semaglutide in heart failure Semaglutide in Patients With Obesity and Heart Failure Across Mildly Reduced or Preserved Ejection Fraction

Potential action mechanisms of semaglutide in the phenotype of heart

23.68

★★★★☆4.8 (126)

In patients with heart failure with preserved ejection fraction and obesity, but without type 2 diabetes, semaglutide treatment has led to larger reductions in heart failure–related symptoms and physical limitations and greater

21.29

★★★★★4.9 (98)

In patients with cardiometabolic #HFpEF, #semaglutide and #tirzepatide reduced the risk of hospitalization for heart failure or all-cause mortality compared to sitagliptin, but tirzepatide offered no additional benefit over semaglutide. https://ja.ma

26.01

★★★★★5.0 (157)

Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials

22.66

★★★★★4.7 (84)

Impact of semaglutide on health outcomes and mood in obese heart failure patients: a retrospective analysis | Clinical Research in Cardiology

22.25

★★★★★4.9 (203)

Semaglutide may reduce heart events more than tirzepatide

28.65

★★★★★5.0 (176)

𝙎𝙏𝙀𝙋-𝙃𝙁𝙥𝙀𝙁 𝙏𝙧𝙞𝙖𝙡 #CCU_TRAIL 𝐒𝐞𝐦𝐚𝐠𝐥𝐮𝐭𝐢𝐝𝐞 𝐢𝐧 𝐏𝐚𝐭𝐢𝐞𝐧𝐭𝐬 𝐰𝐢𝐭𝐡 𝐇𝐞𝐚𝐫𝐭 𝐅𝐚𝐢𝐥𝐮𝐫𝐞 𝐰𝐢𝐭𝐡 𝐏𝐫𝐞𝐬𝐞𝐫𝐯𝐞𝐝 𝐄𝐣𝐞𝐜𝐭𝐢𝐨𝐧 𝐅𝐫𝐚𝐜𝐭𝐢𝐨𝐧 𝐚𝐧𝐝 𝐎𝐛𝐞𝐬𝐢𝐭𝐲 ©️Published August 25, 2023 𝙄𝙣 𝙖𝙙𝙪𝙡𝙩𝙨

24.79

★★★★★4.8 (132)